Skip to main content

The LLS Blog

Read about survivors, research, fundraising and advocacy.

Language Matters: What Supporters Say is Not Always What People with Cancer Hear

Steve Buechler produced our first LLS Community member written content. We are excited to provide this opportunity to other members of our online network as well. Steve shares his own experience as a person diagnosed with AML in the article below.

What’s Next in Blood Cancer: Looking Ahead to 2023

We’ve come a long way and we continue to make substantial progress. The outlook for blood cancer patients is better than ever, but it’s still nowhere near good enough. With more than $233 million dollars currently committed to research into every type of blood cancer, you can be sure LLS

LLS and volunteers cheer California laws promoting health equity

LLS and blood cancer advocates are celebrating after our efforts helped make two bills become law in California, advancing health equity and improving cancer care for thousands.


How LLS and Advocates Helped Secure Landmark Health Reforms

Today, cancer patients—and others with other chronic conditions—are breathing a collective sigh of relief. After years of relentless efforts by LLS staff and blood cancer advocates, President Biden just signed into law the Inflation Reduction Act and its key health provisions which will make healthcare more affordable for millions.

FDA Approves New Option for Difficult to Treat, Rare Form of Childhood Leukemia

The Food and Drug Administration (FDA) approved azacitidine (Vidaza®) for pediatric patients 1 month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML). JMML is an aggressive and difficult to treat disease.

Older Posts